WELG:XETRA:XETRA-Amundi S&P Global Health Care ESG UCITS ETF DR EUR Inc (EUR)

ETF | Others |

Last Closing

USD 11.872

Change

+0.07 (+0.61)%

Market Cap

N/A

Volume

6.28K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.47 (+0.88%)

USD 445.28B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.10 (+0.58%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.10 (+0.34%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.20 (+0.70%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.08 (+0.30%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.39 (-0.84%)

USD 102.61B
8R80:XETRA Amundi Index Solutions - Amund..

-2.60 (-1.81%)

USD 98.84B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.31 (+0.59%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.24 (-0.22%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-2.82 (-0.46%)

USD 80.38B

ETFs Containing WELG:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.95% 87% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.95% 87% B+ 82% B
Trailing 12 Months  
Capital Gain 5.64% 32% F 37% F
Dividend Return 0.90% 11% F 12% F
Total Return 6.55% 33% F 37% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.16% 49% F 50% F
Dividend Return 6.26% 48% F 48% F
Total Return 0.10% 13% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 6.90% 79% B- 83% B
Risk Adjusted Return 90.73% 79% B- 82% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.